Walleye Capital LLC Takes Position in Bicara Therapeutics Inc. $BCAX

Walleye Capital LLC acquired a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 353,226 shares of the company’s stock, valued at approximately $10,487,000.

Other institutional investors also recently bought and sold shares of the company. UBS Group AG lifted its position in Bicara Therapeutics by 97.4% during the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after purchasing an additional 94,829 shares in the last quarter. Candriam S.C.A. purchased a new stake in Bicara Therapeutics in the first quarter worth about $4,750,000. Dimensional Fund Advisors LP increased its position in Bicara Therapeutics by 166.9% in the first quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock worth $2,170,000 after buying an additional 68,327 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Bicara Therapeutics by 26.2% in the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock worth $66,350,000 after buying an additional 692,933 shares during the period. Finally, Orbimed Advisors LLC raised its stake in shares of Bicara Therapeutics by 219.1% in the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock worth $13,273,000 after buying an additional 458,200 shares during the period.

Bicara Therapeutics Stock Up 2.8%

Shares of Bicara Therapeutics stock opened at $24.28 on Friday. The stock’s 50-day simple moving average is $26.15 and its 200-day simple moving average is $21.80. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -7.83 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.82). On average, equities analysts expect that Bicara Therapeutics Inc. will post -3.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BCAX has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the company an “equal weight” rating in a research report on Wednesday. Mizuho increased their target price on shares of Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Guggenheim began coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Finally, Morgan Stanley upped their price target on shares of Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $32.73.

Insiders Place Their Bets

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 28,214 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares of the company’s stock, valued at $5,279,489.46. This trade represents a 13.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This trade represents a 17.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 117,200 shares of company stock worth $3,267,100 in the last three months. 13.80% of the stock is owned by company insiders.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.